Present BEYOND trial results
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“BEYOND trial results presentation expected in 1H 2021”
What we found
Evidence strength A What the grades mean
The company presented results from the BEYOND Phase 2 trial at the European Hematology Association (EHA) 2021 Virtual Congress in June 2021, meeting the first-half 2021 deadline.
-
A Acceleron Pharma Inc. 8-K filed 2021-08-05
“In June, the Companies presented results from multiple abstracts on luspatercept at the European Hematology Association (EHA) 2021 Virtual Congress. Results from the BEYOND Phase 2 trial ... were presented” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- BEYOND trial results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Acceleron Pharma Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C280600-021689 · Corrections policy